arrow
M

Massimo Di Nicola

Fondazione IRCCS Istituto Nazionale dei Tumori
H指数:44
被引数:1.0万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

ECM-Induced IL-23 Drives Immune Suppression in Breast Cancer via Regulating PD-1 on Tregs

ECM诱导的IL-23通过调控Tregs上的PD-1驱动乳腺癌中的免疫抑制

2025-10-030
OAAI
Biomarker and pharmacodynamic activity of the transforming growth factor-beta (TGFβ) inhibitor SAR439459 as monotherapy and in combination with cemiplimab in a phase I clinical study in patients with advanced solid tumors
2024-02-161
OAAI
A Phase 1/1b study of KAZ954 alone and in combination with spartalizumab (PDR001) and taminadenant (NIR178) in patients with advanced gastrointestinal malignancies
2023-12-010
PRE
A PHASE 1 STUDY EXPLORING THE SAFETY AND TOLERABILITY OF THE SMALL MOLECULE PD-L1 INHIBITOR, INCB086550, IN PATIENTS WITH SELECT ADVANCED TUMORS
2022-11-070
OA
Fifteen-year follow-up of relapsed indolent non-Hodgkin lymphoma patients vaccinated with tumor-loaded dendritic cells
2021-06-145
OAAI
A combination of extracellular matrix- and interferon-associated signatures identifies high-grade breast cancers with poor prognosis

细胞外基质和干扰素相关特征的组合可识别预后不良的高级别乳腺癌

2021-02-197
OAAI
Back to simplicity: a four-marker blood cell score to quantify prognostically relevant myeloid cells in melanoma patients

回归简单: 四标记血细胞评分量化黑色素瘤患者预后相关的骨髓细胞

2021-02-1512
OAAI